Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinaseJeffrey D. Carson, Lusong Luo, Kurt R. Auger et al.|Biochemical Journal|2007Cited by 119
Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid LeukemiaRyan G. Kruger, Peter J. Tummino, Helai P. Mohammad et al.|Blood|2013Cited by 30
221 POSTER A novel inhibitor of phosphoinositide 3-kinase for the treatment of cancerK R Auger, Dashyant Dhanak, Liang Luo et al.|European Journal of Cancer Supplements|2008Cited by 5
Abstract C62: Identification of GSK2126458, a highly potent inhibitor of phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR)Steven D. Knight, Dashyant Dhanak, Nicholas D. Adams et al.|Molecular Cancer Therapeutics|2009Cited by 4
Abstract C63: Biological characterization of GSK2126458, a novel and potent inhibitor of phosphoinositide 3-kinase and the mammalian target of rapamycin (mTOR)Mary Ann Hardwicke, Kurt R. Auger, Steven D. Knight et al.|Molecular Cancer Therapeutics|2009Cited by 1